C-Path's Rare & Orphan Disease Conference was 2.5-day conference held Sept. 11-13, that included patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists coming together to gain an understanding of:
- C-Path's Rare and Orphan Disease Program's current and future impact on drug development in rare diseases from the perspectives of patients, regulators and industry partners
- The Critical Path for Rare Neurodegenerative Disease (CP-RND) initiative's first year impact and highlights
- How RDCA-DAP has been enhanced in the last year, and how the platform informs rare disease drug development
Transversal solutions to address bottlenecks in drug development

Visit the conference event page here: [ Ссылка ]. Learn more at [ Ссылка ].

About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org or email info@c-path.org.

#CPath #nonprofit #drugdevelopment #drugrepurposing #drugdiscovery #raredisease #ALS #Duchenne #ataxia #sicklecellanemia #ftd #collaboration #FDA #EMA #globalhealth #huntingtonsdisease #DMD

свернуть